AU716610B2 - Method for producing epothilones, and intermediate products obtained during the production process - Google Patents

Method for producing epothilones, and intermediate products obtained during the production process Download PDF

Info

Publication number
AU716610B2
AU716610B2 AU21493/97A AU2149397A AU716610B2 AU 716610 B2 AU716610 B2 AU 716610B2 AU 21493/97 A AU21493/97 A AU 21493/97A AU 2149397 A AU2149397 A AU 2149397A AU 716610 B2 AU716610 B2 AU 716610B2
Authority
AU
Australia
Prior art keywords
mmol
solution
methyl
chem
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU21493/97A
Other versions
AU2149397A (en
Inventor
Armin Bauer
Oliver M. Bohm
Martin Cordes
Anja Limberg
Dieter Schinzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19636343A external-priority patent/DE19636343C1/en
Priority claimed from DE19645361A external-priority patent/DE19645361A1/en
Priority claimed from DE19645362A external-priority patent/DE19645362A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2149397A publication Critical patent/AU2149397A/en
Application granted granted Critical
Publication of AU716610B2 publication Critical patent/AU716610B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Description

-1- Method for producing epothilones, and intermediate products obtained during the production process The invention relates to a method for producing epothilones, and intermediate products obtained during the production process.
Epothilones 1 (DE 41 38 042 C2) represent a new class of tubulin-stabilising natural substances having a taxol-like action. In particular, their cytotoxic action with respect to medicament-resistant tumour cell lines is of enormous importance for potential application in the treatment of cancer Hofle, N. Bedorf, H. Steinmetz, D. Schomburg, K. Gerth, H. Reichenbach Angew. Chem. 1996, 108, 1671; Angew. Chem. Int. Ed. Engl. 1996, 1567; D. Schinzer "Epothilones New Promising Microtubule-stabilizing Natural Products with Taxol-like Biological Activity", Eur. Chem. Chron. 1996, 1, 7; D.M. Bollag, P.A. McQueney, J. Zhu, O. Hensens, L. Koupal, J. Liesch, M. Goetz, E. Lazarides, C.M. Woods, Cancer Res. 1995, 55, 2325]. Further interesting publications, some only after the priority applications of this Application, are: Acc. Chem. Res. 28, 446 (1995) generally about olefin metathesis, WO 93/10121 and J. Antibiot. 49, 560 (1996) with the isolation of epothilone A and B from natural sources, J. Org. Chem. 38, 2136 (1973) on the synthesis of substituted aldehydes and ketones, Helv. Chim. Acta 4, 1253 (1983) about certain 1,3from Streptomyces spp., Chem. Ber. 100, 720 (1967) about cyclohexanone derivatives, and the intermediate publications Angew. Chem. Int. Ed. 2801 (1996), J. Am. Chem. Soc. 119, 2733 (1997), Tetrahedron Lett. 38, 2061 (1997), Angew. Chem. Int. Ed. 36, 166 (1997), Lieb. Ann. Chem. 2135 (1996), J. Org. Chem. 61, 7998 (1996), J. Org. Chem. 61, 8000 (1996), Angew. Chem. Int. Ed. 35, 2399 (1996) and WO 97/19086.
Epothilones 1 R H, B: R Me) have recently been isolated from Myxobacteria and are obtainable via fermentation. As a result of the very interesting biological properties, the synthesis of epothilones is of the greatest importance. The invention relates to the total synthesis of epothilone A and B 1.
S
N
I f/ olefin metathesis, epoxidation 4 OH
R
N OH 3 aldol reaction esterification O 0 OH O 2 Scheme 1. Retrosynthetic analysis, Schinzer, A. Limberg, O.M. Bbhm, Chem. Eur. J. 1996, 2, 1477].
Epothilones 1 are obtainable in a convergent reaction procedure from the three building blocks 2, 3 and 4. As the retrosynthesis in Scheme 1 shows, building blocks 2 and 3 are linked in a stereoselective aldol reaction. An esterification with fragment 4 yields the almost completely functionalised fragment 17, which is cyclised in a ring-closure metathesis to form deoxy-epothilone A 19. A concluding epoxidation finally yields 1. The key step in the synthesis is the stereoselective aldol reaction of fragments 2 and 3 (obtainable from the commercially available heptenoic acid). Under kinetically controlled reaction conditions in the presence of LDA, exclusively the desired compound 5 having the four correctly positioned centres of asymmetry is obtained in a yield of 70 Here, evidently as a result of a double stereodifferentiation there takes place a chiral overriding of the preferred Cram selectivity of the aldehyde 3, since both reaction partners are used in optically active form.
The invention therefore relates to a method for producing epitholone A or B of the general formula 1
N
0 OH O wherein R hydrogen or a methyl group wherein a thiazolealkyldiene-alcohol derivative of formula 4 Sj
OH
is esterified with a carboxylic acid of general formula 9a
HO
OB O OB 0 OB O OB wherein B benzyl, tetrahydropyranyl and/or a silyl protecting group(s).and R hydrogen or methyl, the resulting ester has the ring closed by means of an olefin metathesis in the presence of a noble metal catalyst, if appropriate the hydroxyl-protecting groups are cleaved, the newly formed double bond is epoxidised and if appropriate the hydroxyl-protecting groups are cleaved.
As silyl protecting groups B there are generally suitable all different trialkyl- or diaryl-alkylsilyl protecting groups, especially the tert-butyl-dimethyl-, trimethyl-silyl and diphenyl-tertbutyl-silyl groups.
-4- The derivatives 4a and 9a are esterified, preferably by the use of DCCI/DMAP, and the resulting ester with the two terminal alkene groups has the ring closed by olefin metathesis, preferably by the use of RuCI 2 (=CHPh)(PCy 3 2 (Grubbs catalyst) Org. Chem. 1996, 61, 3942-3943; Tetrahedron 1996, 52, 7251-7264; J. Am. Chem. Soc., 1995, 117, 12364-12365; J. Am. Chem. Soc., 1995, 117, 2943-2944 and Tetrahedron Lett.; 1994, 35, 3191-3194, J. Am. Chem. Soc., 1996, 118, 6634-6640 and J. Am. Chem. Soc., 1995, 118, 100-110.
The epoxidation of the newly formed double bond is effected preferably by means of peracid, e.g. perchloric acid, or peroxide, e.g. cumene hydroperoxide or dimethyldioxirane.
The invention also includes deoxy-epothilones according to general formula 19a
R
S
N OB O 19a O OB 0wherein B benzyl, p-methoxybenzyl, tetrahydropyranyl and/or a silyl protecting group and S R hydrogen or methyl, S (2-(2,2-dimethyl-[13]dioxan-4-yl)-2-methyl-pentan-3-one) 2, (S)-2-methyl-6-heptenal 3 :0 3
H
o in its optically active form and (S)-2,6-dimethyl-6-heptenal 3a S3a
H
in its optically active form and compounds of general formula 9a
HO
OB
P
I
V
GB
wherein B benzyl, tetrahydropyranyl and/or a silyl protecting group R hydrogen or methyl, and B may have different meanings within the molecule, and compounds of general formula 4a
N
4~:wherein B hydrogen, benzyl, p-methoxybenzyl, tetraliydropyranyl or a silyl protecting group *and (4S,6S)-2-(2 ,2-dimethyl4l 2
O
0 3 a N b O 0 o OH TBSO OTBS O OTBS 7 OH OH 0 OH 6 OH OTBS O OTBS 8 0
HO
0 OTBS O OTBS 9 Scheme 2. a) LDA, THF, -780C, 70%; b) pyridinium p-toluenesulfonate (PPTS), MeOH, RT, 36 h, 88 c) 12 eq. tert-BuMe 2 SiOTf (Tf=trifluoromethanesulfonate), 6 eq. 2,6-lutidine,
CH
2
CI
2 -78°C, 96 d) 0.2 eq. CSA (camphorsulfonic acid), MeOH, CH2C1 2 0°C, 5 h, 82 e) 11 eq. pyridinium dichromate (PDC), DMF, RT, 36 h, 79 The cleavage of the acetonide 5 to form the triol 6 takes place smoothly in the presence of pyridinium p-toluenesulfonate (PPTS). A subsequent trisilylation with TBSOTf and lutidine as auxiliary base yields the desired compound 7. In order to facilitate the oxidation to the acid 9 it is necessary to remove the primary silyl group selectively. This takes place smoothly in the presence of camphorsulfonic acid (CSA) and generates compound 8.
A concluding oxidation with pyridinium dichromate (PDC) produces fragment 9, which is the C1-C12 sub-unit of 1.
-7- TBSO OH a rl TBSO OTBS b TBSO OTBS 12
C
N OTBS
OTBS
d
OH
OTBS
14
S
16
OTBS
e
N
OTBS
f
>N
OH
4 0 Scheme 3. a) TBSCI, imidazole, DMF, RT, 10 h, 98 b) 03, PPh 3 0H 2
CI
2 -78 0 C, 70 c) 1.5 eq. diethyl-(2-methylthiazol-4-yI)methanephosphonate, nBuLi, THE, -78'C RT, d) HF, MeCN, a few splinters of glass, 0 0 C, 87 e) Dess-Martin periodinane, 0H 2 01 2 RT, 1 h, 78 f) 1.85 eq. PPh 3 MeBr/NaNH 2 THE, RT, 20 min., 83 g) 2.5 eq. tetrabutylammonium fluoride (TBAF), molecular sieve 4 A, THE, -780C RT, 99 The (8)-alcohol 10 obtainable via a Sharpless resolution Schinzer, A. Limberg, O.M.
Bohm, Chem. Eur. J. 1996, 2, 1477] was first silylated with TBSCI, then ozonised to the methylketone 12 and reacted in a stereoselective Horner-Wadsworth-Emmons reaction to -8form the tricyclic olefin 13. A selective desilylation with HF in acetonitrile yields compound 14. The desilylation to 14 functions only in the presence of a few splinters of glass; the reaction is evidently catalysed by H 2 SiF 6 Dess-Martin oxidation, followed by a Wittig olefination generates compound 16 which, in a concluding desilylation with TBAF in THF, yields segment 4. The esterification of building blocks 9 and 4 in the presence of DCC and 4-DMAP produces compound 17, which is isolated in stereochemically homogeneous form.
-9- HO N N O 0 OTBSO OTBS
O
4 9 a I OTBS 0 OTBSO0 17
S
N"J OTBS 0 O OTBSO0 18
S
N 1
OH
0 O OH 0 Epothilone C: 19 N .0 0 O OH 0 Epothilone A: 1 Scheme 4. a) 1 .3 eq. dicyclohexylcarbodiimide (DCC), 0.2 eq. 4-dimethylaminopyridine (4-DMAP), CH 2
CI
2 RT, 12 h, 80 b) C1 2 [RuCHPhl(PCY 3 2
CH
2
CI
2 RT, 12 h, 94 E 1 c) HF, MeON, Et 2 O, RT, 12 h, 65 d) dimethyldioxirane, CH 2
CI
2 -350C, 2 h, 48 Ring closure metathesis with CI2[RuCHPh](PCy 3 2 in CH 2
CI
2 yields 18 in the form of a diastereoisomeric mixture E 1 1) in a yield of 94 The total synthesis is concluded by the desilylation with HF in acetonitrile/ether to form 19 and a regio- and stereo-selective epoxidation with dimethyldioxirane to form 1. The main product of this reaction is (-)-epothilone A, which is chromatographically and spectroscopically identical to an authentic sample.
All in all, a strictly convergent synthesis has been described, which allows many options for analogues, which is significant in view of the biological activity. The entire synthesis can be carried out using a type of protecting group (TBS) that is linked or removed in selective reactions. The stereoselective aldol reaction is high and constitutes a further impressive example of the chiral overriding of the aldehyde selectivity with a chiral enolate. The ring closure metathesis to form 18 takes place with an isolated yield of 94 but yields a 1 1 mixture of the Z- and E-isomers. The biologically significantly more active epothilone B 1 (R Me) can be obtained by the same preparation route.
11 Preparation of 2 0 OH OH NaH, TIIF
TBDMSCI
92% OH OTBOMS 441 Me 2 CO, H.
CUSO 4 81%
CICOCOCI,
DMSO, Et 3
N
80%
X>:
O OTBOMS u) BI PC 2 2. NaOH, H 202 42%, 92% ee
OH
~-~OTDMS
43 NaIO 4 OSO 4 76% O~x) EtMgBr, Et 20 80% OH TPAP, NMO 86% O X -12- Working procedures for the synthesis of segment 2 (2-(2,2-Dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentan-3-one) Schinzer, A. Limberg, O.M. Bohm, Chem. Eur. J. 1996, 2, 1477].
The 3-[(tert-butyldimethylsilyl)oxy]propanal 42 is prepared starting from propane-1,3-diol by first monosilylating in accordance with a method of P.G. McDougal, J.G. Rico, Y. Oh, B.D.
Condon, J. Org. Chem. 1986, 51, 3388-3390, to form 3-[(tert-butyldimethylsilyl)oxy]-1propanol 41 which is then oxidised with DMSO/oxalyl chloride to form the aldehyde 42 Jenmalm, W. Berts, Y. Li, K. Luthmann, I. Csoregh, U. Hacksell, J. Org. Chem. 1994, 59, 1139-1148).
Preparation of 1-[(tert-butyldimethylsilyl)oxy]-4,4-dimethyl-hex-5-en-3-ol 43 Brown, P.K. Jadhav, Tetrahedron Lett. 1984, 25, 1215-1218; P.K. Jadhav, K.S. Bhat and P. Thirumalai, H.C. Brown, J. Org. Chem. 1986, 51, 432-439).
500 mg (7.34 mmol, 1 equiv.) of 3-methyl-1,2-butadiene are slowly added dropwise to a suspension, cooled to -250C, of Ipc 2 BH (7.34 mmol, prepared from -pinene [99%, 97% ee] H.C. Brown, M.C. Desai, P.K. Jadhav, J. Org. Chem. 1982, 47, 5065-5069; H.C.
Brown, B. Singaram, J. Org. Chem. 1984, 49, 945-947) in 2.6 ml of THF and the reaction mixture is stirred at -25oC for 6 hours. The THF is then pumped off at RT (14 mm Hg/- 1 hour), (0.5 mm/2 hours) and the residue is dissolved in 10.5 ml of diethyl ether. The solution is cooled to -78°C and 1.382 g (7.34 mmol, 1 equiv.) of aldehyde 42 are added dropwise thereto. The reaction mixture is stirred at -78 0 C for 12 hours and then heated to RT. 10.7 ml of 3N NaOH solution and then 4.4 ml of 30% H 2 0 2 solution are added and the reaction mixture is heated under reflux for 2 hours. The organic phase is separated off, washed with 15 ml of H 2 0 and 15 ml of saturated NaCI solution, dried over MgSO 4 and concentrated. The residue is purified by column chromatography with pentane:ether 2:1, and 800 mg (3.098 mmol) of the alcohol 43 are obtained, corresponding to a yield of 42%.
The determination of the enantiomeric excess was effected by gas chromatographic analysis of the diastereoisomeric compounds which are obtained on esterification of the alcohol with (1R)-(-)-camphanic acid chloride and gave an ee value of 92%.
General data: C 14
H
30 0 2 Si, formula weight 258.47 g/mol 13 C-NMR (100 MHz, CDCI 3 145.69 112.27 78.52 63.29 41.19 33.39 25.89 22.85 22.43 18.17 -5.52 (q) -13- Preparation of 4-(1,1 -dimethyl-allyl)-2,2-dimethyl-[1,3]dioxane 44 278 mg (1.076 mmol) of the alcohol 43 are dissolved in 13 ml of acetone, and 200 mg (2.51 mmol, 2.3 equiv.) of anhydrous CuSO 4 are added. Then 40 drops of a solution of 0.1 ml of glacial acetic acid in 1 ml of CH 2
CI
2 are added dropwise and stirring is carried out at RT for 12 hours. If starting material can still be detected by thin-layer chromatography, further acid solution is added until the reaction is complete. For working up, the reaction mixture is poured into saturated NaHCO 3 solution and the aqueous phase is extracted with DE. The combined organic phases are dried over MgSO 4 and concentrated using a rotary evaporator. The residue is purified by column chromatography with pentane:ether 2:1.
161 mg (0.87 mmol) of the acetonide 44 are obtained, corresponding to a yield of 81%.
General data: C 11
H
20 0 2 formula weight 184.28 g/mol 13 C-NMR (100 MHz, CDC13): 145.10 111.88 98.19 75.32 60.10 39.97 29.80 25.88 22.86 22.45 19.11 (q) Preparation of 2-(2,2-dimethyl-[1,3]dioxan-4-yl)-2-methyl-propionaldehyde 286 mg (1.55 mmol) of the acetonide 44 are dissolved in 18 ml of THF, and 14 ml of aqueous phosphate buffer pH 7 are added. 400 pl (0.
0 3 1 mmol, 0.02 equiv.) of Os0 4 solution in tert-butanol) are added dropwise to the reaction mixture, which is stirred vigorously. After 10 minutes, 996 mg (4.656 mmol, 3 equiv.) of NalO 4 are added in portions over a period of 20 minutes. The mixture is stirred vigorously at RT and after 24 hours and after 48 hours a further 332 mg (each 1.55 mmol, 2x1.0 equiv.) of NalO 4 are added. After hours the phases are separated; the aqueous phase is extracted with ether and the combined organic phases are dried over MgSO 4 and concentrated. The residue is purified by column chromatography with pentane:DE 1:1. 221 mg (1.19 mmol) of the aldehyde are obtained, corresponding to a yield of 76%.
General data: CloH 18 0 3 formula weight 186.25 g/mol 1 C-NMR (100 MHz, CDCI 3 206.09 98.43 72.94 59.75 48.84 29.57 25.57 18.96 18.62 16.46 (q) Preparation of 2-(2,2-dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentan-3-ol 46 At 0°C, 528 p (1.58 mmol, 1.1 equiv.) of a 3M solution of EtMgBr in ether are added to a solution of 268 mg (1.44 mmol) of the aldehyde 45 in 4 ml of diethyl ether. The mixture is stirred at 0°C for 2 hours, heated to RT and stirred for a further one hour. For working up, saturated aqueous NH 4 CI solution is added and then water is added until the precipitate -14dissolves. The aqueous phase is extracted with ether, and the combined organic phases are dried over MgSO 4 and concentrated. The residue is purified by column chromatography with pentane:ether 1:1. 251 mg (1.16 mmol) of the alcohol 46 are obtained, corresponding to a yield of General data: C 12
H
24 0 3 formula weight 216.31 g/mol 13 C-NMR (100 MHz, CsD 6 98.41 79.95 76.65 60.10 40.60 Diastereoisomer 1: 30.04 25.73 24.64 20.03 19.25 15.99 11.67 (q) 13 C-NMR (100 MHz, C 6 De): 98.57 78.85 76.46 60.08 39.93 Diastereoisomer 2: 30.02 25.41 25.08 20.85 20.30 18.90 11.95 (q) Preparation of 2-(2,2-dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentan- 3 -one 2: W.P. Griffith, S.V. Ley, G.P. Whitcombe, A.D. White, J. Chem. Soc., Chem. Commun. 1987, 1625-1627 mg (0.32 mmol) of the alcohol 46 are dissolved in 5 ml of CH 2
CI
2 and 6 4A molecular sieve beads and 66 mg (0.48 mmol, 1.5 equiv.) of 4-methylmorpholine N-oxide (NMO) are added. After stirring for 10 minutes, 6 mg of tetrapropylammonium perruthenoate (VII) (TPAP) (0.016 mmol, 0.05 equiv.) are added and stirring is carried out at RT for 4 hours.
The reaction mixture is then concentrated using a rotary evaporator and purified directly by column chromatography with pentane:ether 1:1. 60 mg (0.28 mmol) of the ethyl ketone 2 are obtained, corresponding to a yield of 86%.
General data: C 12
H
22 0 3 formula weight 214.30 g/mol 13 C-NMR (100 MHz, C 6 De): 213.23 98.42 74.18 59.82 50.44 31.70 30.03 25.55 20.97 19.35 19.04 8.16 (q) Synthesis of 2-methyl-6-heptenal 3 and 3a
R
R 3 R=H I 3a R=Me 0 The preparation is effected following the method of the synthesis of 6-tert-butyldimethylsilyloxy-2-methyl-hexanal 50 Schinzer, A. Limberg, O.M. B6hm, Chem. Eur. J. 1996, 2, 1477].
Synthesis of segment 4: 0 0 NaOH, EtOH 81% 0 HO ONa
TBDMSCI.
imidazole, DMF 86% 0 TBDMSO S.
TBDMS
MeOH. THF
K
2 00 3 90% 0 TBOM SO
OH-
S001 2. benzene 92% 0
TBDMSO
0
LN
,,-BuLi 0 0 II
OTBDMS
1--ly NaHMDS; Mel 82%
OTBDMS
LA.H, Et 2 0 84% HO O B M
CICOCOCI,
DMSO, Et 3
N
87%
OTBDMS
0 Working procedures for the preparation of segment 3: The sodium 6-hydroxyhexanoate is prepared from o-caprolactone in accordance with a procedure of Wulff, KrOger and R~hle, Chem. Ben. 1971, 104, 1387-1 399.
-16- Preparation of 6-[(tert-butyldimethylsilyl)oxy]-hexanoic acid silyl ester A mixture of 2.00 g (12.97 mmol) of sodium 6-hydroxyhexanoate, 25 ml of DMF, 5.87 g (38.93 mmol, 3 equiv.) of TBDMSCI and 5.3 g (77.85 mmol, 6 equiv.) of imidazole is stirred at RT for 48 hours. The reaction mixture is flash-filtered and then purified by column chromatography with pentane:DE 4:1. 3.99 g (11.1 mmol) of the bis-silylated compound 6-[(tert-butyldimethylsilyl)oxy]-hexanoic acid silyl ester are obtained, corresponding to a yield of General data: C 18
H
40 03Si 2 formula weight 360.69 g/mol "C-NMR (100 MHz, CDC13): 174.17 63.00 36.02 32.53 25.95 25.55 25.40 24.91 18.33 17.57 -4.83 -5.32 (q) Preparation of 6-[(tert-butyldimethylsilyl)oxy]-hexanoic acid in accordance with D.R. Morton, J.L. Thompson, J. Org. Chem. 1978, 43, 2102-2106.
A solution of 4.4 g (31.8 mmol, 3.5 equiv.) of K 2 C0 3 in 44 ml of H 2 0 is added to a solution of 3.25 g (9.02 mmol) of the bis-silylated compound 6-[(tert-butyldimethylsilyl)oxy]-hexanoic acid silyl ester in 130 ml of methanol and 44 ml of THF and stirring is carried out at RT for 1 hour. The volume of the reaction solution is then reduced to a quarter in vacuo. Dilution is carried out with 130 ml of saturated NaCI solution and the pH is adjusted to 4-5 with 1M
KHSO
4 solution. Extraction is carried out with diethyl ether. The combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. 2.01 g (8.17 mmol) of 6-[(tert-butyldimethylsilyl)oxy]-hexanoic acid are obtained, corresponding to a yield of General data: C 1 2
H
2 6 03Si, formula weight 246.42 g/mol 1 3 C-NMR (100 MHz, CDCl3): 180.09 62.90 34.05 32.37 25.93 25.31 24.46 18.32 -5.33 (q) Preparation of 6-[(tert-butyldimethylsilyl)oxy]-hexanoyl chloride J. Tanaka, Bull. Chem. Jpn. 1992, 65, 2851-2853 362 mg (3.04 mmol, 1.5 equiv.) of SOCI 2 are added to a solution of 0.5 g (2.03 mmol) of 6- [(tert-butyldimethylsilyl)oxy]-hexanoic acid in 4 ml of benzene and the mixture is heated under reflux for 2 hours. The mixture is allowed to cool and the solvent is distilled off using a rotary evaporator. In order to remove excess SOC12 from the reaction mixture, benzene is again added to the residue and distillation is again carried out. 494 mg (1.865 mmol, 92%) -17of the 6-[(tert-butyldimethylsilyl)oxy]-hexanoyl chloride are obtained. This crude product is reacted further without being purified or characterised.
*(S)-4-lsopropyl-3-propenoyl-oxazolidin-2-one 0 0 Prepared following the method of: D.A. Evans, K.T. Chapman, J. Bisha J. Am. Chem. Soc.
1988, 110, 1238; A. Studer, T. Hintermann, D. Seebach Helv. Chim. Acta 1995, 78, 1185.
6.88 ml of a 1.6M solution of n-BuLi in hexane (11.0 mmol) are slowly added at -780C to a solution of 1.299 g (10.0 mmol) of (S)-4-isopropyl-oxazolidin-2-one in 15 ml of absolute THF.
The solution is stirred at -78°C for 30 minutes, 1.22 ml (15.0 mmol) of acrylic acid chloride are added dropwise thereto and the mixture is heated to room temperature and hydrolysis is carried out with 50 ml of saturated NH 4 CI solution. Extraction is carried out three times using ml of Et 2 0 each time. After drying over MgSO 4 the solvent is removed. Purification by flash chromatography with pentane/Et 2 0 (10:1) yields 1.63 g (8.9 mmol, 89 of (S)-4-Isopropyl-3-(6-methylhept-6-enoyl)-oxazolidin-2-one 21a
O_
S0 21a Prepared following the method of: A. Studer, T. Hintermann, D. Seebach Helv. Chim. Acta 1995, 78, 1185 47 mg (1.9 mmol) of Mg turnings are stirred at room temperature (or with occasional heating) in 1.5 ml of absolute THF with 283 mg (1.9 mmol) of 4-bromo-2-methyl-1-butene until all the magnesium has dissolved. To this Grignard solution there is added at a suspension of 197 mg (1.00 mmol) of CuBr-Me 2 S in 1.5 ml of absolute THF. Stirring is carried out at that temperature for 30 minutes; 117 mg (0.64 mmol) of 20 in 2 ml of absolute THF are added and the mixture is stirred at -10 0 C for 16 hours and hydrolysis is carried out with 10 ml of saturated NH 4 CI solution. Extraction is carried out three times using 20 ml of Et 2 0 each time. After drying over MgSO 4 the solvent is removed. Purification by flash chromatography with pentane/Et20 (15:1) yields 128 mg (0.51 mmol, 79 of 21a.
-18- Hept-6-enoyl chloride 5.11 g (40.26 mmol, 2 eq.) of oxalyl chloride are added to a solution of 2.58 g (20.13 mmol) of hept-6-enoic acid in 10 ml of CH2C1 2 then stirred at RT for 1 hour and at 40°C for 1 hour.
The mixture is allowed to cool and the solvent is distilled off at 5 mbar. 2.95 g (20.13 mmol, 100 of the acid chloride are obtained. This crude product is reacted without further purification.
General data: C 7
H
1 1 CIO, formula weight 146.62 g/mol (S)-3-Hept-6-enoyl-4-isopropyl-oxazolidin-2-one 21 O N 21 A. Gonzalez, Synth. Comm. 1991, 21, 1353-1360 A solution of 2.08 g (16.10 mmol, 1 eq.) of (4S)-4-isopropyl-oxazolidin-2-one in 15 ml of THF is cooled to -780C and 11.6 ml (18.52 mmol, 1.15 eq.) of a 1.6M solution of n-BuLi solution in hexane are added dropwise thereto. Then at -780C a solution of 2.95 g (20.13 mmol, 1.25 eq.) of hept-6-enoyl chloride in 10 ml of THF is added dropwise. The reaction solution is heated to RT and poured into saturated NaCI solution. The aqueous phase is extracted with ether, the combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column chromatography with PE DE 3 1. 3.55 g (14.82 mmol, 92 of the oxazolidinone 21 are obtained in the form of a colourless oil.
General data: C 13
H
21
NO
3 formula weight 239.31 g/mol -19- (4S,2'S)-4-Isopropyl-3-(2-methyl-hept-6-enoyl)-oxazolidin-2-one 22 analogous to preparation 25 and (4S,2'S)-4-isopropyl-3-(2,6-dimethyl-hept-6-enoyl)-oxazolidin-2-one 22a 0 N 22 R=H v v22a R=Me 0 0 D.A. Evans, A.E. Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 9.02 ml (9.02 mmol, 1.15 equiv.) of a 1M solution of NaHMDS in THF are cooled to -78°C, and a solution, cooled to 0°C, of 1.88 g (7.84 mmol) of oxazolidinone 21 in 8 ml of THF is added dropwise thereto. Stirring is carried out at -780C for 1 hour; 5.57 g (39.22 mmol, equiv.) of Mel dissolved in 2 ml of THF are added and stirring is carried out at -78 0 C for 4 hours. The reaction mixture is then quenched with saturated NH 4 CI solution, extracted with diethyl ether, dried over MgSO 4 and concentrated. The residue is purified by column chromatography with PE DE 4 1. 1.51 g (5.96 mmol, 76 of the methylated compound 22 are obtained.
General data: C 14
H
23
NO
3 formula weight 253.34 g/mol Compound 22a is prepared analogously. 1.56 g (5.84 mmol, 73 of 22a are obtained from 2.03 g (8.0 mmol) of 21a.
(S)-2-Methyl-hept-6-en-1-ol 23 and (S)-2,6-dimethylhept-6-en-1-ol 23a
R
s23 R=H OH 23a R=Me D.A. Evans, A.E. Weber J. Am. Chem. Soc. 1986, 108, 6757-6761 5.83 ml (5.83 mmol, 2 eq.) of a 1M suspension of LAH in diethyl ether are slowly added to a solution, cooled to 0°C, of 738 mg (2.91 mmol) of the methylated compound 22 in 10 ml of diethyl ether. The reaction mixture is quenched by the addition of 221 ml of water, 221 ml of aqueous NaOH solution and 663 ml of water. Flash filtration is then carried out over Celite with diethyl ether and purification is carried out by column chromatography with pentane DE 3 1. 299 mg (2.33 mmol, 80 of the alcohol 23 are obtained in the form of a colourless liquid.
General data: C 8
H
16 0, formula weight 128.21 g/mol Compound 23a is prepared analogously. 331 mg (2.32 mmol, 83 of 23a are obtained from 748 mg (2.80 mmol) of 22a.
(S)-2-Methyl-hept-6-enal 3 and (S)-2,6-dimethylhept-6-enal 3a
R
A 3 R=H 3a R=Me 0 1.269 g (2.99 mmol, 1.3 eq.) of Dess-Martin periodinane (1,1,1-triacetoxy-1,1-dihydro-1,2benziodoxol-3(1H)-one) are added to a solution of 295 mg of alcohol 23 (2.30 mmol) in 5 ml of CH 2
CI
2 and stirring is carried out at RT for 25 minutes. For working-up, one volume equivalent of phosphate buffer pH 7 is added. The aqueous phase is extracted with CH 2
CI
2 the combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column chromatography with pentane DE 10 1.
224 mg (1.77 mmol, 77 of the aldehyde are obtained in the form of a colourless liquid.
General data: C 8
H
14 0, formula weight 126.20 g/mol Compound 3a is prepared analogously. 199 mg (1.42 mmol, 71 of 3a are obtained from 284 mg (2.00 mmol) of 23a.
21 Preparation of 4:
S
4 OH TBSO OHi a TBSO OTBS b r'a1 TBSO OTBS 12
C
OTBS
N
OTBS
d p.- OH N OTBS 14
N
16
OTBS
e ~0
N
OTBS
f
OH
4 Synthesis of segment 4: 3-(Tert-butyldimethylsilyl)oxy]-propanal Synthesis by monosilylation of 1,3-propanediol and subsequent Swern oxidation of the resulting 3-[(tert-butyldimethylsilyl)oxy]-1 -propanol.
General data: C 9
H
20
O
2 Si; formula weight 188.36; CAS No. [89922-82-71 13 0C-NMR (100 MHz, CDC 3 d=202.05 57.42 46.58 25.82 18.23 -5.43 (q) I Tert-butyldimethylsi IyI)oxy]-3-hyd roxy-4-methyl-4-pentene 0.2 ml of 2-bromopropene is added under N 2 to 443 mg of Mg turnings (18.2 mmol) and 1 .5 ml of absolute THIF so that the reaction starts. With occasional cooling, a solution of -22- 1.7 ml of 2-bromopropene (22 mmol in total) in 6 ml of absolute THF is slowly added dropwise until all the Mg turnings have dissolved. While the mixture is still warm, a solution of 2.862 g of 1 (15.2 mmol) in 6 ml of absolute THF is added dropwise. Stirring is carried out at RT for 6 hours. 25 ml of saturated NH 4 CI solution are then added to the reaction solution and stirring is carried out for 10 minutes. The mixture is poured into 30 ml of saturated NH 4
CI
solution and extracted twice with ether. The combined organic phases are washed once with saturated NH 4 CI solution and once with saturated NaCI solution. Drying over MgSO 4 concentration in vacuo and purification by flash chromatography (ether:pentane 1:6) are carried out. 2.749 g of 2 (11.9 mmol; 79% of theory) are obtained in the form of a colourless oil.
General data: C 12
H
26 0 2 Si; formula weight 230.43 13 C-NMR (100 MHz, CDCI 3 d=147.10 110.39 75.21 62.17 36.79 25.89 18.41 -5.49 -5.53 (q) (S)-1,3-Di-[(tert-butyldimethylsilyloxy)]-l-methyl-4-pentene 11 TBSO OTBS 11 946 mg (6.28 mmol, 1.3 eq.) of tert-butyldimethylchlorosilane are added to a solution of 1.173 g (4.83 mmol) of (S)-l-[(tert-butyldimethylsilyloxy)]-4-methyl-4-penten-3-ol 10 and 855 mg (12.56 mmol, 2.6 eq.) of imidazole in 15.0 ml of absolute DMF. The mixture is stirred at room temperature for 16 hours. 50 ml of an aqueous 1M KHSO 4 solution are added and extraction is carried out four times using 50 ml of Et 2 0 each time. The combined ether extracts are dried over MgSO 4 After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with pentane/- Et 2 0 As an alternative to that aqueous working-up, the reaction mixture can be chromatographed directly. In accordance with both variants of working-up, 1.643 g (4.73 mmol, 98 of 11 are obtained.
-23- (S)-3,5-Di-[(tert-butyldimethylsilyloxy)]-pentan-2-one 12 TBSO OTBS 12 Ozone in 02 is passed at -780C through a solution of 1.610 g (4.67 mmol) of 11 in 200 ml of absolute dichloromethane (dry ice/acetone cooling bath). When starting compound 11 can no longer be detected in the solution by thin-layer chromatography, 3.89 g (14.83 mmol) of triphenylphosphine are added and the cooling bath is removed. The reaction mixture is heated slowly to room temperature and the solvent is distilled off in vacuo. Flash chromatography of the residue through a column of silica gel with pentane/Et20 (50:1) yields 1.135 g (3.27 mmol, 70 of 12.
Diethyl-(2-methylthiazol-4-yl)-methanephosphonate 'k P(OEt)2 Preparation is effected starting from 4-chloromethyl-2-methylthiazole, which is known in the literature, analogously to the procedure for 4-bromomethyl-2-methylthiazole. From 7.381 g mmol) of 4-chloromethyl-2-methylthiazole there are obtained 9.971 g (40 mmol, 80 of diethyl-(2-methylthiazol-4-yl)-methanephosphonate.
(S,4E)-4-[3,5-Di-(tert-butyldimethylsilyloxy)-2-methyl-pent-1-enyl]-2-methylthiazole 13
S
OTBS
13 2.94 ml of n-BuLi (1.6M solution in hexane) are added dropwise at -780C to a solution of 1.170 g (4.70 mmol) of diethyl-(2-methylthiazol-4-yl)-methanephosphonate in 15 ml of absolute THF. The mixture is stirred at -78°C for 45 minutes and then a solution of 1.135 g (3.27 mmol) of 12 in 10 ml of absolute THF is slowly added dropwise thereto; the mixture is heated to room temperature and stirred at room temperature for a further 12 hours. 100 ml of saturated NH 4 CI solution are added to the reaction mixture and extraction is carried out -24four times using 80 ml of Et20 each time. The combined ether extracts are washed with saturated NaCI solution and dried over MgSO 4 After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with pentane/dichloromethane 1.090 g (2.47 mmol, 75 of 13 are obtained.
Tert-butyldimethylsilyloxy)-4-methyl-5-(2-methylthiazol-4-yl)-pent-4-en-1-ol 14 N% OH 14
OTBS
0.45 ml of hydrofluoric acid (40 is added dropwise at -200C to a solution of 442 mg mmol) of 13 in 40 ml of acetonitrile. After the addition of a few splinters of glass or 0.045 ml of hexafluorosilicic acid (30 stirring is carried out at 0°C until starting compound 13 can no longer be detected in the solution by thin-layer chromatography. 50 ml of saturated NaHCO 3 solution are added to the reaction mixture and extraction is carried out four times using 80 ml of Et 2 0 each time. The combined ether extracts are dried over MgSO 4 After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with Et 2 0. 284 mg (0.87 mmol, 87 of 14 are obtained.
(S,4E)-3-(Tert-butyldimethylsilyloxy)-4-methyl-5-(2-methylthiazol-4-yl)-pent-4-ena
OTBS
A solution of 284 mg (0.87 mmol) of 14 in 5.0 ml of absolute CH 2
CI
2 is added to a suspension of 478 mg (1.127 mmol, 1.3 eq.) of Dess-Martin periodinane (1,1,1-triacetoxy- 1,1-dihydro-1,2-benziodoxol-3(1H)-one) in 5.6 ml of absolute CH 2
CI
2 and stirring is carried out at room temperature for 60 minutes. After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with pentane/Et 2 0 222 mg (0.68 mmol, 78 of 15 are obtained.
Tert-butyldimethylsilyloxy)-2-methyl-hexa-1,5-dienyl]-2-methyl-thiazole 16 16
OTBS
440 mg (1.06 mmol, 1.85 eq.) of a mixture of equimolar amounts of sodium amide and methyltriphenylphosphonium bromide are stirred at room temperature for 30 minutes in ml of absolute THF. A solution of 185 mg (0.57 mmol) of 15 in 5.0 ml of absolute THF is added and stirring is continued for a further 20 minutes; 20 ml of saturated NaHCO 3 solution are added and extraction is carried out four times using 30 ml of Et 2 0 each time. The combined ether extracts are dried over MgSO 4 After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with 151 mg (0.47 mmol, 83 of 16 are obtained.
2-Methyl- -(2-methyl-thiazol-4-yl)-hexa-1,5-dien-3-ol 4 4 OH 1.18 ml (1.18 mmol, 2.5 eq.) of a 1M TBAF solution in THF are stirred at room temperature for 20 minutes in 10 ml of absolute THF with activated molecular sieve 4A in order to bind residual water of the TBAF solution. There is then added dropwise to the resulting anhydrous TBAF solution, at -780C, a solution of 151 mg (0.47 mmol) of 16. The mixture is slowly heated to room temperature, with stirring, and hydrolysed with 50 ml of saturated
NH
4 CI solution when starting compound 16 can no longer be detected in the solution by thinlayer chromatography. Extraction is carried out three times using 50 ml of Et20 each time.
After drying over MgSO 4 the solvent is removed. Purification by flash chromatography with pentane/Et 2 0 (20:1) yields 97 mg (0.465 mmol, 99 of 4.
The preparation of compounds of general formula 4a
N
4a
OB
-26- (B represents benzyl, p-methoxybenzyl, tetrahydropyranyl or a silyl protecting group; e.g.
trialkyl- or diaryl-alkyl-silyl protecting groups, especially tert-butyl-dimethyl-, trimethylsilyl and diphenyl-tert-butyl-silyl groups) is effected from S 4
OH
by the use of conventional protecting group techniques of etherification, see also Schinzer, A. Limberg, O.M. Bohm, Chem. Eur. J. 1996, 2, 1477).
Preparation of 5 and compounds of general formula 9a (4'S,4R,5S,6S)-2-(2,2-dimethyl-[1,3]dioxan-4-yl)-5-hydroxy-2,4,6-trimethyl-undec-10-en- 3-one 5 and (4'S,4R,5S,6S)-2-(2,2-dimethyl-[1,3]dioxan-4-yl)-5-hydroxy-2,4,6,10-tetramethyl-undec- 10-en-3-one analogously to Scheme 2.
R=H
0 O 5a R=Me O O O OH C.H. Heathcock, C.T. Buse, W.A. Kleschick, M.C. Pirrung, J.E. Sohn, J. Lampe J. Org. Chem. 1980, 45, 1066.
943 microlitres (1.509 mmol, 0.98 eq.) of a 1.6M solution of n-BuLi in hexane are added dropwise at 0°C to a solution of 153 mg (1.509 mmol, 0.98 eq.) in 1.5 ml of THF and the mixture is stirred for 30 minutes before being cooled to -78oC. 330 mg (1.540 mmol, 1 eq.) of (S)-2-(2,2-dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentan-3-one 2 dissolved in 1 ml of THF are then slowly added dropwise. The solution is stirred at -780C for 1 hour. 194 mg (1.540 mmol, 1 eq.) of (S)-2-methyl-hept-6-enal 3 are then added dropwise and stirring is carried out at -780C for 45 minutes. The reaction solution is quenched by the addition of saturated NH 4 CI solution and heated to RT. The aqueous phase is extracted with ether; the -27combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column chromatography with pentane diethyl ether 3 1. 369 mg (1.084 mmol, 70 of the aldol product 5 are obtained in the form of a colourless oil.
General data: C 20
H
36 0 4 formula weight 340.50 g/mol Compound 5a is prepared analogously. 386 mg (1.09 mmol, 64 of 5a are obtained from 238 mg (1.70 mmol) of 3a.
(3S,6R,7S,8S)-1,3,7-Trihydroxy-4,4,6,8-tetramethyl-tridec-12-en-5-one 6 and (3S,6R,7S,8S)-1,3,7-trihydroxy-4,4,6,8,12-pentamethyl-tridec-12-en-5-one 6a 6 R=H OH OH O OH 6a R=Me L.A. Paquette, D.R. Sauer, D.G. Cleary, M.A. Kinsella, C.M. Blackwell, L.G. Anderson J. Am. Chem. Soc. 1992, 114, 7375-7387. 95 mg (0.378 mmol, 1.3 eq.) of PPTS are added to a solution of 100 mg (0.294 mmol) of the aldol product 5 in 14 ml of MeOH and the mixture is stirred at RT for 36 hours and then quenched by the addition of 33 drops of saturated NaHCO 3 solution. The mixture is concentrated using a rotary evaporator and the residue is taken up in ether. Washing is carried out with saturated NaCI solution and the aqueous phase is extracted with ether. The combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column O chromatography with diethyl ether. 78 mg (0.260 mmol, 88 of the triol 6 are obtained in the form of a colourless oil.
General data: C 17
H
32 0 4 formula weight 300.44 g/mol Compound 6a is prepared analogously. 77 mg (0.246 mmol, 91 of 6a are obtained from 96 mg (0.270 mmol) of -28- (3S,6R,7S,8S)-1,3,7-Tri-(tert-butyldimethylsilyloxy)-4,4,6,8-tetramethyl-tridec-1 one I and (3S,6R,7S,8S)-1,3,7-tri-(tert-butyldimethylsilyloxy)-4,4,6,8,12-pentamethyltridec-12-en-5-one 7a 7 R=H OTBS I O OTBS 7a R=Me
OTBS
Yuanwei Chen, Pierre Vogel, J. Org. Chem. 1994, 59, 2487-2496 963 mg (8.99 mmol, 12 eq.) of 2,6-lutidine and 1188 mg (4.49 mmol, 6 eq.) of tert-butyldimethylsilyltrifluoromethanesulfonate are slowly added dropwise to a solution, cooled to -780C, of 225 mg (0.749 mmol) of the triol 6 in 13 ml of CH 2
CI
2 The mixture is stirred at -780C for 30 minutes and at OoC for 3 hours and quenched with saturated NaHCO 3 solution.
The aqueous phase is extracted with CH 2
CI
2 The combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column chromatography with pentane diethyl ether 30: 1. 462 mg (0.719 mmol, 96 of the trisilylated product 7 are obtained in the form of a colourless oil.
General data: C 35
H
74 0 4 Si 3 formula weight 643.22 g/mol Compound 7a is prepared analogously. 423 mg (0.644 mmol, 99 of 7a are obtained from 204 mg (0.650 mmol) of 6a.
(3S,6R,7S,8S)-3,7-Di-(tert-butyldimethylsilyloxy)-1 -hydroxy-4,4,6,8-tetramethyl-tridec- 12-en-5-one 8 and (3S,6R,7S,8S)-3,7-di-(tert-butyldimethylsilyloxy)-1 -hydroxy- 4,4,6,8,12-penta-methyl-tridec-12-en-5-one 8a 8 R=H OH 6TBS 8a R=Me
OTBS
K.C. Nicolaou, K.R. Reddy, G. Skokotas, F. Sato, Xiao J. Am. Chem. Soc. 1992, 114, 7935. A solution of 156 mg (0.243 mmol) of the trisilylated compound 7 in 6.5 ml of MeOH and 6.5 ml of CH 2 01 2 is cooled to OoC and 11 mg of camphorsulfonic acid (0.0485 mmol, 0.2 eq.) are added. After being stirred for 5 hours at 00C, the mixture is quenched by the addition of saturated NaHCO 3 solution. The aqueous phase is extracted with CH 2 C1 2 The combined organic phases are dried over MgSO 4 and the solvent is distilled using a rotary evaporator. The residue is purified by column chromatography with pentane diethyl ether -29- =3 1. 105 mg (0.199 mmol, 82 of the alcohol 8 are obtained in the form of a colourless oil.
General data: C 29
H
60 04Si 2 formula weight 528.96 g/mol Compound 8a is prepared analogously. 101 mg (0.186 mmol, 80 of 8a are obtained from 152 mg (0.232 mmol) of 7a.
3
S,
6
R,
7
S,
8
S)-
3 7 -Di-(tert-butyldimethylsilyloxy)-4,4,6,8-tetramethyl-5-oxo-tridec-12enoic acid 9 and (3S,6R,7S,8S)-3,7-di-(tert-butyldimethylsilyloxy)-4,4,6,8,12-pentamethyl-5-oxo-tridec-12-enoic-acid 9a HO 9 R= 9 R=H o o 6TBS 9a R=Me
OTBS
E.J. Corey, G. Schmidt, Tetrahedron Lett. 1979, 399-402 2371 mg (6.30 mmol, 11 eq.) of PDC dissolved in 3 ml of DMF are added dropwise at 0°C to a solution of 303 mg (0.573 mmol) of alcohol 8 in 6 ml of DMF. The mixture is stirred at RT for 36 hours and then poured into 50 ml of saturated NaCI solution, diluted with water and extracted with CH 2
CI
2 The combined organic phases are dried over MgSO 4 and the solvent is distilled off using a rotary evaporator. The residue is purified by column chromatography with pentane diethyl ether 2 1. 247 mg (0.455 mmol, 79 of the acid 9 are obtained in the form of a colourless oil.
General data: C 29
H
58 ssSi 2 formula weight 542.94 g/mol S Compound 9a is prepared analogously. 273 mg (0.490 mmol, 83 of 9a are obtained from 320 mg (0.590 mmol) of 8a.
30 (3 S,6R, 7S, 8S)-3,7-D i-tert-b utyld imethyls ilyl oxy-4,4,6,8-tetram ethyl -5-oxo-tridec-1 2enoic acid (1 S)-1 -methyl-2-(2-methyl-thiazol-4-yI)-vinyl]-but-3-eny ester 17 and *(3S,6R,7S8S).37.d..terj.butyidmethysjiyoxy.446,8,2-pentamethyl-5-oxo-tridec-1 2enoic acid (1 S)-1 -m ethyl -2 -(2-methyl -th iazoI-4-yI) -vinyl] -b ut-3-enyI ester 1 7a
\R
.,OTBS
17 R=H 0OTBSJ 17a R=Me Esterification according to B. Neises, W. Steglich Angew. Chem. 1978, 90, 556.
72 mg (0.348 mmol, 1.3 eq.) of dicyclohexylcarbodiimide are added at 000 to a solution of 145 mg (0.268 mmol) of acid 9, 56 mg (0.268 mmol) of alcohol 4 and 6.5 mg (0.0536 mmol, 0.2 eq.) of DMAP in 1.5 ml of absolute 0H 2
CI
2 Stirring is carried out at 000 for 10 minutes and at room temperature for 12 hours. After removal of the solvent and flash chromatography of the residue with pentane/Et 2 O 157 mg (0.214 mmol, 80 of the ester 17 are obtained.
Ester 17a is prepared analogously. 166 mg (0.222 mmol, 74 of 17a are obtained from 167 mg (0.30 mmol) of 9a and the equimolar amount of 4.
(4S,7R,8S,9S,1 GS,1 3Z)-4,8-Di-tert-butyldimethylsilyloxy-5,5,7,9-tetramethyl-I methyl-2-(2-methyl-thiazol-4-yI)-vinyl]-1 -oxa-cyclohexadec-1 3-ene-2,6-dione 18 and *(4S7R8S,9S,16S,1 3Z)-4,8-di-tert-butyldimethylsilyloxy-5,5,7,9,1 3-pentamethy-1 I -methyl-2-(2-methyl-thiazol-4-y)-vinyl]-1 -oxa-cyclohexadec-1 3-ene-2,6-dione 1 8a
R
.ODTBS
0 18 R=H 0 0TB8D 18a R=Me An Ar-saturated solution of 49.3 mg (0.067 1 mmol) of the ester 17 in 33.5 ml of absolute 0H 2 C1 2 (corresponding to a substrate concentration of 0.002M) is stirred for 16 hours under an argon atmosphere with 3.3 mg (6 mol Of 01 2 [Ru=CHPh](PCy 3 2 (Cy =cyclohexyl).
After removal of the solvent and flash chromatography of the residue with pentane/Et 2
O
-31 44 mg (0.0630 mmol, 94 of compound 18 are obtained in the form of a 1:1 mixture with its E-isomer.
*49.0 mg (0.068 mmol, 68 of a mixture of 18a and its E-isomer are obtained analogously from 74.8 mg (0.100 mmol) of 17a.
(4S,7R,8S,9S,16S,1Z)-4,8-Dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-methyl-2-(2-methylthiazol-4-yl)-vinyl]-1-oxa-cyclohexadec-13-ene-2,6-dione 19 ("Epothilone and *(4S,7R,8S,9S,16S,13Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2methyl-thiazol-4-yl)-vinyl]-1-oxa-cyclohexadec-13-ene-2,6-dione 19a (Epothilone D")
R
,0H 19 R=H O 19a R=Me 0 OH O 0.27 ml of hydrofluoric acid (40 is added dropwise at 0°C to a solution of 35.3 mg (0.05 mmol) of 18 (Z:E mixture 1:1) in 2.4 ml of acetonitrile/Et20 After the addition of a few splinters of glass or 0.027 ml of hexafluorosilicic acid (30 stirring is carried out at room temperature for 17 hours. 10 ml of saturated NaHCO 3 solution are added to the reaction mixture and extraction is carried out three times using 20 ml of Et20 each time. The combined ether extracts are dried over MgSO 4 After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with Et 2 O. 16.5 mg (0.0325 mmol, 65 of 19 are obtained in the form of al.1 Z:E mixture.
*20.7 mg (0.042 mmol, 70 of 19a (in the form of a Z:E mixture) are obtained analogously from 43.2 mg (0.06 mmol) of 18a.
Epothilone A 1 and *epothilone B la
Q.
R
O-OH
1 R=H 0 OH O la R=Me 0.36 ml (0.035 mmol, 1.2 eq.) of a freshly prepared solution of dimethyldioxirane in acetone is added dropwise, with stirring, at -35oC to a solution of 14.3 mg (0.03 mmol) of 19 (1:1 Z:E -32mixture) in 2.5 ml of CH2C1 2 The mixture is stirred at -35°C for 2 hours, then 5 ml of a 10 aqueous solution of iron(ll) sulfate are added and extraction is carried out three times using ml of CH 2
CI
2 each time. After the solvent has been distilled off in vacuo, the residue is subjected to flash chromatography through a column of silica gel with Et20. 7.1 mg (0.0144 mmol, 48 of epothilone A are obtained.
*6.2 mg (0.0123 mmol, 41 of epothilone B are obtained analogously from 14.8 mg (0.03 mmol) of 19a.
The invention relates also to stereoisomers of the compounds according to the claims, as they are customarily obtained during the synthesis.

Claims (6)

  1. 2. A deoxy-epothilone according to general formula 19a o o ooo a. a. a. a.* a a a a a.* a. a o• wherein and B benzyl, p-methoxybenzyl, tetrahydropyranyl and/or a silyl protecting group R hydrogen or methyl.
  2. 3. 2-(2,2-Dimethyl-[1,3]dioxan-4-yl)-2-methyl-pentan-3-one 2
  3. 4. (S)-2-Methyl-6-heptenal 3 H in its optically active form. (S)-2,6-Dimethyl-6-heptenal 3a OY 3a H in its optically active form.
  4. 6. A compound of general formula 9a R HO 0 OB O OB 9a wherein B benzyl, tetrahydropyranyl and/or a silyl protecting group R hydrogen or methyl, and B may have different meanings within the molecule.
  5. 7. A compound of the general formula 4a 4a OB wherein S. B hydrogen, benzyl, p-methoxybenzyl, tetrahydropyranyl or a silyl protecting group.
  6. 8. (4S,6S)-2-(2,2-dimethyl-[1,3] dioxan-4-yl)-5-hydroxy-2,4,6-trimethyl- undecan-3-one DATED this 30th day of November, 1999 Novartis Aktiengesellschaft By DAVIES COLLISON CAVE ytent Attorneys for the Applicant
AU21493/97A 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process Ceased AU716610B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19636343 1996-08-30
DE19636343A DE19636343C1 (en) 1996-08-30 1996-08-30 New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
DE19645362 1996-10-28
DE19645361A DE19645361A1 (en) 1996-08-30 1996-10-28 Production of epothilone compounds with taxol-like activity
DE19645361 1996-10-28
DE19645362A DE19645362A1 (en) 1996-10-28 1996-10-28 Production of epothilone compounds with taxol-like activity
PCT/DE1997/000111 WO1998008849A1 (en) 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process

Publications (2)

Publication Number Publication Date
AU2149397A AU2149397A (en) 1998-03-19
AU716610B2 true AU716610B2 (en) 2000-03-02

Family

ID=27216622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21493/97A Ceased AU716610B2 (en) 1996-08-30 1997-01-15 Method for producing epothilones, and intermediate products obtained during the production process

Country Status (5)

Country Link
EP (1) EP0923583A1 (en)
JP (1) JP2001500851A (en)
AU (1) AU716610B2 (en)
NZ (1) NZ334821A (en)
WO (1) WO1998008849A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846952B2 (en) 1996-11-18 2010-12-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2178093T5 (en) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) EPOTILON DERIVATIVES AND ITS PREPARATION.
JP4579351B2 (en) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis of epothilone and its intermediates and analogs and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001512723A (en) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト Novel epothilone derivatives, their preparation and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
WO1999067253A2 (en) * 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
KR20010094763A (en) 1999-02-11 2001-11-01 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 Epothilon Derivatives, Method For The Production And The Use Thereof As Pharmaceuticals
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AU772750C (en) 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2004521122A (en) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー Parenteral formulation of epothilone analog
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
EE200300396A (en) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Use of epothilone derivatives for the treatment of refractory tumors
CA2438598A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
NZ527557A (en) * 2001-02-27 2005-05-27 Biotechnolog Forschung Gmbh Degradation of epothilones and ethynyl substituted epothilones
CZ305799B6 (en) 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for treating proliferative diseases
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co Epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2471509A1 (en) 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
DE60330651D1 (en) 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR101406635B1 (en) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
NZ549925A (en) 2004-04-07 2010-08-27 Novartis Ag Inhibitors of IAP
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007038459A2 (en) 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
US9006224B2 (en) 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
RU2452492C2 (en) 2006-04-05 2012-06-10 Новартис Аг COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER
EP2004163B1 (en) 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
NZ572299A (en) 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
CN102036953B (en) 2008-03-24 2015-05-06 诺华股份有限公司 Arylsulfonamide-based matrix metalloprotease inhibitors
EA019033B1 (en) 2008-03-26 2013-12-30 Новартис Аг Hydroxamate-based inhibitors of deacetylases b
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
ES2475945T3 (en) 2009-06-26 2014-07-11 Novartis Ag Imidazolidin-2-1,3-disubstituted derivatives as CYP inhibitors 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en) 2009-08-12 2016-05-17 Novartis Ag Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
JP2013503129A (en) 2009-08-26 2013-01-31 ノバルティス アーゲー Tetra-substituted heteroaryl compounds and their use as MDM2 and / or MDM4 modulators
CN102596951B (en) 2009-11-04 2015-04-15 诺华股份有限公司 Heterocyclic sulfonamide derivatives useful as MEK inhibitors
US8614239B2 (en) 2009-12-08 2013-12-24 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN102633792A (en) * 2011-02-15 2012-08-15 天津尚德药缘科技有限公司 Method for preparing epothilone D and B
CA2834224A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17.alpha.-hydroxylase/c17,20-lyase inhibitors
JP2014517004A (en) 2011-06-09 2014-07-17 ノバルティス アーゲー Heterocyclic sulfonamide derivatives
CN106110332B (en) 2011-06-10 2018-11-30 梅尔莎纳医疗公司 Protein-polymer-drug conjugate
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
MX339302B (en) 2011-09-15 2016-05-19 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase.
CN104080787B (en) 2011-11-29 2016-09-14 诺华股份有限公司 Pyrazolo pyrrolidine compound
SG11201402237WA (en) 2011-12-22 2014-09-26 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
WO2013096049A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140104047A (en) 2011-12-23 2014-08-27 노파르티스 아게 Compounds for inhibiting the interaction of bcl2 with binding partners
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US20140350014A1 (en) 2011-12-23 2014-11-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
UY34591A (en) 2012-01-26 2013-09-02 Novartis Ag IMIDAZOPIRROLIDINONA COMPOUNDS
CN104302634B (en) 2012-05-15 2017-02-08 诺华股份有限公司 Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
PE20210667A1 (en) 2012-05-15 2021-04-05 Novartis Ag BENZAMIDE DERIVATIVES FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY
AU2013261129B2 (en) 2012-05-15 2016-05-12 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
AU2013261128B2 (en) 2012-05-15 2015-11-12 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
CN104321325B (en) 2012-05-24 2016-11-16 诺华股份有限公司 Pyrrolopyrrole alkanone compound
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CA2885969C (en) 2012-10-02 2021-04-06 Epitherapeutics Aps Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
US9650339B2 (en) 2013-02-27 2017-05-16 Gilead Sciences, Inc. Inhibitors of histone demethylases
CN103232464B (en) * 2013-03-29 2015-08-19 四川农业大学 Taxoid compound and preparation thereof and the application in cancer therapy drug
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
SG11201509350RA (en) 2013-06-11 2015-12-30 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
AU2014331714B2 (en) 2013-10-11 2019-05-02 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2943979A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP2017512804A (en) 2014-03-31 2017-05-25 ギリアード サイエンシーズ， インコーポレイテッド Inhibitors of histone demethylase
CA2944401A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
BR112017003442A2 (en) 2014-08-27 2017-11-28 Gilead Sciences Inc compounds and methods for inhibiting histone demethylases
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018237262A1 (en) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
AU2019262520A1 (en) 2018-05-04 2021-01-14 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
EP4382167A3 (en) 2018-05-04 2024-08-28 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
US20230021500A1 (en) 2018-10-29 2023-01-26 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
FR3087650B1 (en) 2018-10-31 2021-01-29 Bio Even FLAVINE ADENINE DINUCLEOTIDE (FAD) FOR USE FOR THE PREVENTION AND / OR TREATMENT OF CANCER
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for high click release speed and yield
DK3983363T3 (en) 2019-06-17 2024-06-24 Tagworks Pharmaceuticals B V CONNECTIONS FOR QUICK AND EFFECTIVE CLICK RELEASE
JP2024532537A (en) 2021-09-06 2024-09-05 ヴェラクサ バイオテック ゲーエムベーハー Novel aminoacyl-tRNA synthetase mutants for genetic code expansion in eukaryotes
WO2023094525A1 (en) 2021-11-25 2023-06-01 Veraxa Biotech Gmbh Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240119102A (en) 2021-12-08 2024-08-06 유럽피안 몰레큘러 바이올로지 래보러토리 Hydrophilic Tetrazine-Functionalized Payload for Preparation of Targeting Conjugates
AU2023221765B2 (en) 2022-02-15 2024-09-19 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (en) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
ES2178093T5 (en) * 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) EPOTILON DERIVATIVES AND ITS PREPARATION.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL PHYSICS LETTERS 1981 VOL. 77(1) PAGES 131-134 *
JOURNAL OF ORGANIC CHEMISTRY 1973 V.38(12) PAGES 2136-2143 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846952B2 (en) 1996-11-18 2010-12-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
US8076490B2 (en) 1996-11-18 2011-12-13 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions

Also Published As

Publication number Publication date
NZ334821A (en) 2000-12-22
AU2149397A (en) 1998-03-19
WO1998008849A1 (en) 1998-03-05
EP0923583A1 (en) 1999-06-23
JP2001500851A (en) 2001-01-23

Similar Documents

Publication Publication Date Title
AU716610B2 (en) Method for producing epothilones, and intermediate products obtained during the production process
US6043372A (en) Intermediates in the process for preparing epothilones
Schinzer et al. Total synthesis of (−)‐epothilone A
Schinzer et al. Syntheses of (−)‐Epothilone B
Nicolaou et al. Total synthesis of epothilone E and related side-chain modified analogues via a Stille coupling based strategy
Hanessian et al. The total synthesis of (+)-ionomycin
Patel et al. Synthesis of the proposed penultimate biosynthetic triene intermediate of monensin A
Paterson Polyketide synthesis using the boron-mediated, anti-aldol reactions of lactate-derived ketones: Total synthesis of (-)-ACRL toxin IIIB
US6441186B1 (en) Epothilone analogs
Nicolaou et al. Total Synthesis of 16‐Desmethylepothilone B, Epothilone B10, Epothilone F, and Related Side Chain Modified Epothilone B Analogues
Evans et al. Enantioselective total synthesis of callipeltoside A: two approaches to the macrolactone fragment
Paterson et al. The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: the CD-spiroacetal segment
Cases et al. Synthetic studies towards furanocembrane diterpenes. A total synthesis of bis-deoxylophotoxin
Paterson et al. Phorboxazole B synthetic studies: construction of C (1–32) and C (33–46) subtargets
Chakraborty et al. Radical-induced Opening of Trisubstituted Epoxides: Application in the Synthesis of C1–C12 Segment of Epothilones
US7001916B1 (en) Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
De Brabander et al. Bryostatins: the asymmetric synthesis of the C1-C9 and C17-C27 fragments
Paterson et al. The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: the AB-spiroacetal segment
Martin et al. The 12, 13‐Diol Cyclization Approach for a Truly Stereocontrolled Total Synthesis of Epothilone B and the Synthesis of a Conformationally Restrained Analogue
Kuramochi et al. A convergent total synthesis of epolactaene: an application of the bridgehead oxiranyl anion strategy
Paterson et al. The stereocontrolled total synthesis of altohyrtin A/spongistatin 1: the southern hemisphere EF segment
Williams et al. Studies for the enantiocontrolled preparation of substituted tetrahydropyrans: applications for the synthesis of leucascandrolide A macrolactone
Marshall et al. Enantioselective synthesis of carbohydrate precursors via 1, 2: 2, 3-bis-epoxide intermediates
Motoyoshi et al. First total synthesis and determination of the absolute configuration of mueggelone
Schinzer et al. Synthesis of Furano‐Epothilone D

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent
MK14 Patent ceased section 143(a) (annual fees not paid) or expired